Earlier this year we highlighted
a fragment optimization success story against a G protein-coupled receptor
(GPCR) which made no use of structural information. Due to the difficulty of
crystallizing these membrane-bound proteins, structures have been rare for this
large class of drug targets. Advances in crystallography are starting to change
that. In a recent open-access Chem. Commun. paper, Jens Carlsson and collaborators
at Uppsala University and the US National Institutes of Health make use of the
increasing availability of such structures to develop potent, selective
inhibitors.
The researchers were interested in
A1 and A2A adenosine receptors (A1AR and A2AAR),
targets for a variety of ailments from cancer to cardiovascular diseases. (A2AAR
was the subject of this blog post a few months ago.) In the current study, the
researchers wanted to know whether structures and molecular dynamics (MD)
simulations could guide production of selective inhibitors.
Previous computational and
experimental work from the authors had yielded compound 1, with low micromolar
activity against A1AR and 7-fold selectivity over A2AAR.
Crystal structures of both these proteins are available, though not bound to
the small molecule. Docking studies suggested that the ligand would make
similar interactions to both proteins, but that there might be an opportunity
for increased selectivity towards A1AR due to the presence of a smaller
threonine residue compared with a methionine in A2AAR. Nine analogs
were designed to grow into this lipophilic pocket, and free energy perturbation
and MD simulations suggested that they would have improved affinity for A1AR.
This turned out to be the case when the molecules were made and tested in
radioligand binding assays.
Although compounds 5 and 9 were
more potent, selectivity was not improved. MD simulations suggested this might
be due to the small size of the fragments, which could be accommodated in A2AAR
by slight shifts in the binding modes. To try to anchor compounds within the
pocket, the researchers grew off the phenyl ring, leading to molecules such as
compound 15. Borrowing from this molecule and compound 9 led to compound 22,
the most potent and selective molecule in the series. (A separate effort led to
a somewhat weaker but A2AAR-selective ligand.) Both molecules were found
to be antagonists when tested in cells, which was expected given that the crystal
structures used for modeling were in the inactive conformation.
The correlation between predicted
and measured binding energies was respectable, with a mean unsigned error (MUE)
of 1.08 kcal/mol and Spearman’s rank correlation coefficient (ρ) of 0.8 for 24
compounds. Selectivity predictions were also impressive at MUE = 0.48 kcal/mol
and ρ = 0.85.
This is a nice illustration of using
computational methods to improve the affinity of a fragment by more than three
orders of magnitude while also increasing selectivity. This particular system
is probably on the easier side; we blogged about previous research from this
group on A2AAR back in 2013. The researchers note that proteins with
larger binding sites and weaker ligands are likely to be more challenging. It will
be fun to see efforts towards Class B GPCRs, for example.
No comments:
Post a Comment